ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2018, Vol. 27 ›› Issue (5): 457-462.DOI: 10.3969/j.issn.1006-298X.2018.05.013

• 论文 • 上一篇    下一篇

钠-葡萄糖共转运蛋白2抑制剂的代谢调控及心肾保护作用

  

  • 出版日期:2018-10-28 发布日期:2018-11-14

Beneficial of sodiumglucose cotransporter2 inhibitors in metabolic,renal and cardiovascular considerations

  • Online:2018-10-28 Published:2018-11-14

摘要:

钠-葡萄糖共转运蛋白2(SGLT2)抑制剂是一类通过抑制近端肾小管葡萄糖重吸收发挥作用的新型降糖药。除降糖、降压、改善代谢因素和减轻葡萄糖毒性外,此类药物还可通过管球反馈,直接调节肾内血流动力学,减轻肾脏高压力、高灌注,发挥肾脏和心脏保护作用。新近的临床试验结果表明,此类药物可减少心血管事件和肾脏终点事件。其对代谢和血流动力学的影响有望为慢性肾脏病的治疗开拓新领域。

 

关键词: 钠-葡萄糖共转运蛋白2抑制剂, 糖尿病, 慢性肾脏病, 肾脏保护

Abstract:

sodiumglucose cotransporter2 (SGLT2) inhibitors are a new class of antihyperglycemic drugs which reduce glucose via inhibition of tubular glucose reabsorption.In addition to lowering glucose,reducing blood pressure and ameliorating glucotoxicity,SGLT2 inhibitors also exert direct effects on intrarenal haemodynamics via tubuloglomerular feedback.By blocking the transport of sodium in the proximal tubular,SGLT2 inhibitors decrease intraglomerular pressure and normalize hyperfiltration,suggesting a renoprotective effect in diabetic kidney disease.Results from recent clinical trials demonstrated that SGLT2 inhibitors reduce the risk of cardiovascular events and the renal composite endpoint.The effects of SGLT2 inhibitors on metabolism and haemodynamics may start a new era in therapeutics for chronic kidney disease.

Key words: sodium-glucose, cotransporter-2 inhibitors, diabetes mellitus, chronic kidney disease, renoprotective effect